UK nuclear medicine survey, 1992–93

UK nuclear medicine survey 2003–2004

“…NRPB carried out a thorough national survey of nuclear medicine practice over 20 years ago in collaboration with BNMS and the Hospital Physicist's Association (now IPEM) [1]. No comprehensive national survey has been published since 1990, although there was a partial update of the 1989-1990 survey in 1992-1993 [3], a survey of radionuclide therapy in 1995 [4], several surveys of nuclear cardiology, the latest being for 1997 [5], and a local survey of nuclear medicine practice in the South Thames Health Region in 1996-1997 [6]. No comprehensive national survey has been published since 1990, although there was a partial update of the 1989-1990 survey in 1992-1993 [3], a survey of radionuclide therapy in 1995 [4], several surveys of nuclear cardiology, the latest being for 1997 [5], and a local survey of nuclear medicine practice in the South Thames Health Region in 1996-1997 [6].…”

“…(2) to determine the collective effective dose to the UK population from nuclear medicine and the relative contributions of different procedures; (3) to compare the average activities administered by nuclear medicine departments with the diagnostic reference levels (DRLs) recommended in the Notes for Guidance issued by the Administration of Radioactive Substances Advisory Committee (ARSAC) [8]; (4) to review the makes, types and ages of gamma cameras in current use and their capability for SPECT and PET imaging; (5) to examine staffing levels in radiopharmacies and nuclear medicine departments in the UK.…”

Radionuclide Developments

“…Most nuclear medicine diagnostic studies use tracers labelled with technetium-99m [ 1 ] . The characteristics of this isotope are still closest to the optimum required for current equipment.…”

“…It may represent down-regulation of contractile function in response to reduced resting myocardial blood flow. The flow metabolism mismatch was initially described with 1 Wider availability of this technique should be evaluated as a cost-effective diagnostic algorithm for identifying patients with chronic ischaemia and LV dysfunction who are suitable for surgery.…”

“…Treatment delays the development of new sites of pain by over 28 weeks because 8 9 S r is taken up at sites of active bone repair, whether or not they are painful [ 7 2 ] . Three more agents, 1 Table 1). …”